{"analyses":[{"ciLowerLimit":"0.55","ciNumSides":"TWO_SIDED","ciPctValue":"98.22","ciUpperLimit":"0.90","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0008","paramType":"Hazard Ratio (HR)","paramValue":"0.70","statisticalMethod":"Stratified Cox Proportional hazard model"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.25","upperLimit":"13.86","value":"10.84"},{"groupId":"OG001","lowerLimit":"16.49","upperLimit":"27.63","value":"20.76"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"353"}],"units":"Participants"}],"description":"The time between the date of randomization and the date of first documented recurrence (local urothelial tract, local non-urothelial tract or distant), or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo","id":"OG000","title":"Placebo"},{"description":"Nivolumab 240mg IV Q2W","id":"OG001","title":"Nivolumab"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants","reportingStatus":"POSTED","timeFrame":"approximately up to 48 months","title":"Disease Free Survival (DFS)","type":"PRIMARY","unitOfMeasure":"Months"}